Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 410 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sterile water Clear all
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion

NCT01128972
View directory record Official record
Conditions
Tooth Erosion
Interventions
Sodium fluoride, Sodium monoflurophosphate, Sterile water
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 1, 2015 · Synced Oct 22, 2026, 11:47 AM EDT
Completed No phase listed Observational

Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

NCT03276481
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Oral microbiota assessment, Comprehensive chemical gustometry, Measurement of salivary flow, Surveys assessing taste disturbances
Diagnostic Test · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 22, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus

NCT03701074
View directory record Official record
Conditions
Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
Interventions
Ibuprofen and acetaminophen, Ibuprofen and placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
5 Days to 21 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 22, 2026, 11:47 AM EDT
Recruiting Phase 1 Interventional

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

NCT06361108
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
YJ001 for Spray Use, Placebo of YJ001 for Spray Use
Drug
Lead sponsor
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fredericksburg, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

NCT00660192
View directory record Official record
Conditions
Refractory Migraine
Interventions
Botox, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 3 Interventional

Lactobacillus GG in the Prophylaxis of Ventilator Associated Pneumonia

NCT00613795
View directory record Official record
Conditions
Pneumonia, Ventilator Associated Pneumonia
Interventions
Lactobacillus GG, placebo
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

Study of KCC Peptide Application in the Colon

NCT02156557
View directory record Official record
Conditions
Colon Polyps, Colorectal Cancer, Inflammatory Bowel Disease (IBD)
Interventions
Colon KCC Heptapeptide
Biological
Lead sponsor
Danielle Kim Turgeon
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 22, 2026, 11:47 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

NCT05351164
View directory record Official record
Conditions
Lipomatosis, Multiple Symmetrical
Interventions
Metreleptin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
Up to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Not applicable Interventional

Ablation of Prostate Tissue Utilizing Sterile Water Vapor in Patients With Intermediate Risk Localized Prostate Cancer

NCT04087980
View directory record Official record
Conditions
Prostate Cancer
Interventions
Poseidon System
Device
Lead sponsor
Francis Medical Inc.
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Baltimore, Maryland • Minneapolis, Minnesota • Woodbury, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Simulated Clinical Use Testing on the DropSafe Safety Pen Needle

NCT03803488
View directory record Official record
Conditions
Needle Stick
Interventions
DropSafe safety pen needle
Device
Lead sponsor
HTL-Strefa S.A.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Golden Valley, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Expanded Dryvax Dilution Study in Previously Vaccinated Adults

NCT00050505
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
32 Years to 70 Years
Enrollment
927 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
7
States / cities
Oakland, California • Stanford, California • Torrance, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001

NCT03126318
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
COR-001, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 22, 2026, 11:47 AM EDT
Recruiting Phase 4 Interventional

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

NCT06941870
View directory record Official record
Conditions
Factor VIII Deficiency
Interventions
Efanesoctocog alfa
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 11:47 AM EDT
Recruiting Phase 2 Interventional

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT05428007
View directory record Official record
Conditions
Melanoma, Unresectable Melanoma
Interventions
Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

NCT05569759
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
zetomipzomib, placebo, zetomipzomib in open-label extension
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine

NCT01290055
View directory record Official record
Conditions
Yellow Fever
Interventions
Yellow fever vaccine, Deuterium (70% enriched 2H2O) labeled water
Biological · Other
Lead sponsor
Sri Edupuganti
Other
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 22, 2026, 11:47 AM EDT
Withdrawn Not applicable Interventional

Self-discontinuation of Urinary Catheters in a Rural Population

NCT07041151
View directory record Official record
Conditions
Post-Operative Urinary Retention
Interventions
At-home Foley Catheter Self-Removal with Passive Void Trial, In-Office Foley Catheter Removal and Backfill Void Trial
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Lebanon, New Hampshire • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 22, 2026, 11:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

TumorGlow Intraoperative Molecular Imaging (IMI)

NCT04723810
View directory record Official record
Conditions
Tumor, Solid
Interventions
Indocyanine Green
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Results available

Inulin for Infections in the Intensive Care Unit

NCT03865706
View directory record Official record
Conditions
Antibiotic Resistant Infection, Nosocomial Infection, Pathogen Transmission, Nutrition Disorders, Critical Illness, Sepsis
Interventions
Inulin Oral Suspension, Placebo Oral Suspension, Broad-spectrum antibiotics
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Results available

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

NCT01751126
View directory record Official record
Conditions
Vernal Keratoconjunctivitis
Interventions
NOVA22007 ''Ciclosporin'', Placebo
Drug
Lead sponsor
Santen SAS
Industry
Eligibility
4 Years to 18 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Glendale, California • Irvine, California • Rancho Cordova, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

NCT07090824
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions
Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects

NCT02124278
View directory record Official record
Conditions
Healthy
Interventions
PUL-042 Inhalation Solution
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 22, 2026, 11:47 AM EDT